一种转录激活域的脂皮多米米特选择性地破坏了同活性剂Med25的蛋白质-蛋白质相互作用
Olivia N Pattelli1,2, Estefanía Martínez Valdivia1,2, Matthew S Beyersdorf1,2
1Life Sciences Institute, University of Michigan, Ann Arbor, MI 48109, USA.
Angewandte Chemie (International ed. in English)
|March 25, 2024
概括
像LPPM-8这样的脂类胺基药可以通过脂肪酸进行修改,以有效抑制Med25蛋白质与蛋白质的相互作用. 这一进步为研究Med25生物学和三阴性乳腺癌提供了新的工具.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药用化学 医学化学
背景情况:
- 短的两性结合转录协活性剂,但其亲和力和选择性较低.
- 这限制了它们作为蛋白质与蛋白质相互作用 (PPI) 的合成调节剂的使用.
研究的目的:
- 为了增强脂胺基因药物 (LPPMs) 对辅激剂的亲和力和抑制潜力.
- 调查LPPMs在抑制Med25 PPI中的结构-活性关系.
- 评估LPPM-8在三阴性乳腺癌中的治疗潜力.
主要方法:
- 合成和N终端修改一个有分支脂肪酸的heptameric lipopeptidomimetic (LPPM-8).
- afinity 测量 (Ki) 用于量化 LPPM-8 与 Med25 联合激活剂的结合.
- 细胞测试以评估Med25激活剂PPI的抑制和三阴性乳腺癌模型中的基因调节.
主要成果:
- 与未经修改的相比,LPPM-8对Med25 (Ki从100μM>到4μM) 的亲和力增加了超过20倍.
- 脂质结构,序列和C端功能影响了LPPM-8的结构倾向和抑制功效.
- 在癌细胞模型中,LPPM-8通过其激活器相互作用域参与Med25并稳定了全长蛋白质,抑制了Med25调节基因.
结论:
- 脂肪酸修饰显著增强了LPPM作为联合激活剂PPI的抑制剂.
- LPPM-8作为一个有价值的工具来探索Med25和调解器复杂的功能.
- 脂类药物代表了开发激活剂-协同激活剂复合物的抑制剂的有希望的策略.
相关概念视频
Co-activators and Co-repressors
7.3K
Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
7.3K
Eukaryotic Transcription Inhibitors
9.8K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
9.8K
Eukaryotic Transcription Activators
11.0K
Transcription activators are proteins that promote the transcription of genes from DNA to RNA. In most cases, these proteins contain two separate domains ‒ a domain that binds to DNA and a domain for activating transcription; however, in some cases, a single domain is responsible for both binding and activation of transcription, as seen in the glucocorticoid receptor and MyoD.
The binding domains are capable of recognizing and interacting with regulatory sequences on the DNA. These...
The binding domains are capable of recognizing and interacting with regulatory sequences on the DNA. These...
11.0K
RNA Polymerase II Accessory Proteins
9.2K
Proteins that regulate transcription can do so either via direct contact with RNA Polymerase or through indirect interactions facilitated by adaptors, mediators, histone-modifying proteins, and nucleosome remodelers. Direct interactions to activate transcription is seen in bacteria as well as in some eukaryotic genes. In these cases, upstream activation sequences are adjacent to the promoters, and the activator proteins interact directly with the transcriptional machinery. For example, in...
9.2K
Prokaryotic Transcriptional Activators and Repressors
8.4K
8.4K
Covalently Linked Protein Regulators
6.8K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
6.8K


